Gene therapy for Parkinson's disease: Disease modification by GDNF family of 
ligands

Kirik, Deniz; Cederfjall, Erik; Halliday, Glenda; Petersen, Asa

doi:10.1016/j.nbd.2016.09.008

Item

ITEM ACTIONSEXPORT

Add to Basket

Please note that a newer version of this item is available:
https://pure.mpg.de/pubman/item/item_2387968_5

DetailsSummary

Released

Journal Article

Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands

MPS-Authors

/persons/resource/persons202399

Cederfjall, Erik
Department: Molecules-Signaling-Development / Klein, MPI of Neurobiology, Max Planck Society;

External Resource

http://www.sciencedirect.com/science/article/pii/S0969996116302224
(Publisher version)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Kirik, D., Cederfjall, E., Halliday, G., & Petersen, A. (2017). Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 97, 179-188. doi:10.1016/j.nbd.2016.09.008.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002C-5151-9

Abstract

Gene transfer is a promising drug delivery method of advanced therapeutic entities for Parkinson's disease. One advantage over conventional therapies, such as peripheral delivery of the dopamine pre-cursor L-DOPA, is site specific expression of proteins with regenerative, disease-modifying and potentially neuroprotective capacity. Several clinical trials have been performed to test the capacity of glial-cell line derived neurotrophic factor and neurturin to rescue degenerating dopaminergic neurons in the substantia nigra and their axon terminals in the striatum by delivery of these neurotrophic factors either as purified protein or by means of viral vector mediated gene delivery to the brain. Although gene therapy approaches tested so far have been shown to be safe, none met their primary endpoints in phase II clinical trials designed and powered to test the efficacy of the intervention. Within the scope of this review we aim to describe the state-of-the-art in the field, how different technical parameters were translated from pre-clinical studies in non-human primates to clinical trials, and what these trials taught us regarding important factors that may pave the way to the success of gene therapy for the treatment of Parkinson's disease. (C) 2016 Elsevier Inc. All rights reserved.